Cargando…
The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy
One of the hallmarks of cancer cells is their ability to evade cell death via apoptosis. The inhibitor of apoptosis proteins (IAPs) are a family of proteins that act to promote cell survival. For this reason, upregulation of IAPs is associated with a number of cancer types as a mechanism of resistan...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017284/ https://www.ncbi.nlm.nih.gov/pubmed/31947615 http://dx.doi.org/10.3390/cells9010207 |
_version_ | 1783497166714568704 |
---|---|
author | Michie, Jessica Kearney, Conor J. Hawkins, Edwin D. Silke, John Oliaro, Jane |
author_facet | Michie, Jessica Kearney, Conor J. Hawkins, Edwin D. Silke, John Oliaro, Jane |
author_sort | Michie, Jessica |
collection | PubMed |
description | One of the hallmarks of cancer cells is their ability to evade cell death via apoptosis. The inhibitor of apoptosis proteins (IAPs) are a family of proteins that act to promote cell survival. For this reason, upregulation of IAPs is associated with a number of cancer types as a mechanism of resistance to cell death and chemotherapy. As such, IAPs are considered a promising therapeutic target for cancer treatment, based on the role of IAPs in resistance to apoptosis, tumour progression and poor patient prognosis. The mitochondrial protein smac (second mitochondrial activator of caspases), is an endogenous inhibitor of IAPs, and several small molecule mimetics of smac (smac-mimetics) have been developed in order to antagonise IAPs in cancer cells and restore sensitivity to apoptotic stimuli. However, recent studies have revealed that smac-mimetics have broader effects than was first attributed. It is now understood that they are key regulators of innate immune signalling and have wide reaching immuno-modulatory properties. As such, they are ideal candidates for immunotherapy combinations. Pre-clinically, successful combination therapies incorporating smac-mimetics and oncolytic viruses, as with chimeric antigen receptor (CAR) T cell therapy, have been reported, and clinical trials incorporating smac-mimetics and immune checkpoint blockade are ongoing. Here, the potential of IAP antagonism to enhance immunotherapy strategies for the treatment of cancer will be discussed. |
format | Online Article Text |
id | pubmed-7017284 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70172842020-02-28 The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy Michie, Jessica Kearney, Conor J. Hawkins, Edwin D. Silke, John Oliaro, Jane Cells Review One of the hallmarks of cancer cells is their ability to evade cell death via apoptosis. The inhibitor of apoptosis proteins (IAPs) are a family of proteins that act to promote cell survival. For this reason, upregulation of IAPs is associated with a number of cancer types as a mechanism of resistance to cell death and chemotherapy. As such, IAPs are considered a promising therapeutic target for cancer treatment, based on the role of IAPs in resistance to apoptosis, tumour progression and poor patient prognosis. The mitochondrial protein smac (second mitochondrial activator of caspases), is an endogenous inhibitor of IAPs, and several small molecule mimetics of smac (smac-mimetics) have been developed in order to antagonise IAPs in cancer cells and restore sensitivity to apoptotic stimuli. However, recent studies have revealed that smac-mimetics have broader effects than was first attributed. It is now understood that they are key regulators of innate immune signalling and have wide reaching immuno-modulatory properties. As such, they are ideal candidates for immunotherapy combinations. Pre-clinically, successful combination therapies incorporating smac-mimetics and oncolytic viruses, as with chimeric antigen receptor (CAR) T cell therapy, have been reported, and clinical trials incorporating smac-mimetics and immune checkpoint blockade are ongoing. Here, the potential of IAP antagonism to enhance immunotherapy strategies for the treatment of cancer will be discussed. MDPI 2020-01-14 /pmc/articles/PMC7017284/ /pubmed/31947615 http://dx.doi.org/10.3390/cells9010207 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Michie, Jessica Kearney, Conor J. Hawkins, Edwin D. Silke, John Oliaro, Jane The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy |
title | The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy |
title_full | The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy |
title_fullStr | The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy |
title_full_unstemmed | The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy |
title_short | The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy |
title_sort | immuno-modulatory effects of inhibitor of apoptosis protein antagonists in cancer immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017284/ https://www.ncbi.nlm.nih.gov/pubmed/31947615 http://dx.doi.org/10.3390/cells9010207 |
work_keys_str_mv | AT michiejessica theimmunomodulatoryeffectsofinhibitorofapoptosisproteinantagonistsincancerimmunotherapy AT kearneyconorj theimmunomodulatoryeffectsofinhibitorofapoptosisproteinantagonistsincancerimmunotherapy AT hawkinsedwind theimmunomodulatoryeffectsofinhibitorofapoptosisproteinantagonistsincancerimmunotherapy AT silkejohn theimmunomodulatoryeffectsofinhibitorofapoptosisproteinantagonistsincancerimmunotherapy AT oliarojane theimmunomodulatoryeffectsofinhibitorofapoptosisproteinantagonistsincancerimmunotherapy AT michiejessica immunomodulatoryeffectsofinhibitorofapoptosisproteinantagonistsincancerimmunotherapy AT kearneyconorj immunomodulatoryeffectsofinhibitorofapoptosisproteinantagonistsincancerimmunotherapy AT hawkinsedwind immunomodulatoryeffectsofinhibitorofapoptosisproteinantagonistsincancerimmunotherapy AT silkejohn immunomodulatoryeffectsofinhibitorofapoptosisproteinantagonistsincancerimmunotherapy AT oliarojane immunomodulatoryeffectsofinhibitorofapoptosisproteinantagonistsincancerimmunotherapy |